HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials, Survey Says

The results may be useful to design more patient-centered clinical trials assessing the effects of gene therapy in Huntington’s patients.

Aug 8, 2019 | By Marta Figueiredo | Huntington’s Disease News

Eligible Huntington’s disease patients would likely participate in a gene therapy trial regardless of the study design, but they are more inclined toward those with less invasive interventions and without a placebo group, a questionnaire-based study suggests.

The results may be useful to design more patient-centered clinical trials assessing the effects of gene therapy in Huntington’s patients.

The study, “Attitudes of Potential Participants Towards Molecular Therapy Trials in Huntington’s Disease,” was published in the Journal of Huntington’s Disease.

While a new therapy might face obstacles to its development during clinical trials, a significant proportion of studies fail because of the complexity of patient recruitment and lack of patient participation.

There is a growing effort to incorporate the patient perspective into clinical trial design in order to develop studies that better integrate patients’ needs and preferences.

With the development of new gene or molecular therapies to halt or prevent the development of Huntington’s disease — mainly administered through more invasive procedures — it is important to understand patients’ concerns and willingness to participate in these trials.

“In order to optimize feasibility [of clinical trials], it is important to first understand how potential study participants feel about these new trial designs, with interventions that might involve a higher potential risk but also higher potential reward,” Tanya M. Bardakjian, the study’s first author and a senior genetic counselor in the Department of Neurology at Perelman School of Medicine at the University of Pennsylvania, said in a press release.

Researchers at Penn designed a questionnaire to evaluate how patient clinical status, study design, and therapy goals can influence the willingness of eligible Huntington’s patients to participate in gene therapy trials.

The anonymous survey was distributed through the Huntington’s Disease Society of America website. It mainly consisted of multiple-choice questions and scale responses involving hypothetical scenarios based on current or future therapeutic interventions for Huntington’s disease.

Such interventions included therapy administered through pills, directly into the bloodstream, through the spinal cord, or directly into the brain. The survey also involved a scenario where the clinical trial had a placebo group.

Researchers collected the demographic, clinical, and genetic data of 87 people who responded to the survey and classified them according to disease stage: 36 had been diagnosed with Huntington’s disease, 18 were pre-symptomatic carriers of Huntington’s mutations, and 33 had no symptoms but were at risk of developing the condition. Respondents had a mean age of 46.9 years and were highly educated.

Most respondents reported they would be likely or very likely to participate in clinical trials, regardless of study design or therapy goal. However, all three groups showed a more favorable attitude toward clinical studies with less invasive and frequent therapies, and those without a placebo.

Researchers suggested that giving patients the option to receive the experimental therapy once the placebo period ends may help counteract the negative effect of having a placebo group within a trial.

Participants who knew they carried Huntington’s mutation and would eventually develop the disease were significantly more positive toward participation in clinical trials, except those with higher risk or lower benefit.

The results also showed that participants had a positive view of the motivations that drive the investigators who conduct these trials, believing they work for the patients’ benefit over their own personal or professional gain.

Despite the study’s limitations, such as a small sample size with highly educated participants, researchers say their findings likely reflect the global opinion of Huntington’s patients.

“We believe that a patient-centered trial design, through the inclusion of appropriate education and communication to ensure participants and advocates are informed and engaged, is likely to have a positive impact on recruitment,” Bardakjian said.

The study was supported by a grant from the Precise Medicine Special Interest group of the National Society of Genetic Counselors.

TRNDS 2019

University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642

Date: Friday, September 13
Time: 7:30 am – 4:00pm

TRNDS News

Sign-up for TRNDS updates and rare disease news

  • New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
    READ MORE
  • Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
    READ MORE
  • NIH launches 5-year, $10 million study on acute flaccid myelitis
    READ MORE
  • Study refines ALS risk among first-degree relatives of patients with disease
    READ MORE
  • NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
    READ MORE
  • Speeding Up Drug Discovery for Brain Diseases
    READ MORE
  • NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
    READ MORE
  • Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
    READ MORE
  • Jsyne Gershkowitz, Amicus Therapeutics, TRNDS 2019
    (Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
    READ MORE
  • PJ Brooks, NCATS, NIH, TRNDS
    Meet TRNDS 2019 Speaker PJ Brooks
    READ MORE
  • Rare Pediatric Disease PRVs: FDA Updates Guidance
    READ MORE
  • Batten Disease Study
    Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
    READ MORE
  • C-Path and NORD Collaborate to Launch Rare Disease Data Platform
    READ MORE
  • TRNDS 2019 speaker Tauna Batiste, BDSRA
    Meet TRNDS Speaker Tauna Batiste
    READ MORE
  • HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
    READ MORE
  • Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
    READ MORE
  • 'Dr. Google' Helps Some Patients Diagnose a Rare Disease
    READ MORE
  • Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
    READ MORE
  • Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
    READ MORE
  • Netflix's Medical Investigation Docuseries 'Diagnosis'
    READ MORE
  • NIH All of Us Project Tops 270,000 Sign-ups
    READ MORE
  • FDA Cancer Office Taps Syapse for Real-world Evidence Development
    READ MORE
  • Gene Linked to Rare Neurological Disorder May Play a Role in Alzheimer’s
    READ MORE
  • Gene Therapy Developers Issue Principles for Human Genome Editing
    Gene Therapy Developers Issue Principles for Human Genome Editing
    READ MORE
  • Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes
    READ MORE
  • Benjjamin Schlatka MC10 TRNDS
    TRNDS Speaker Benjamin Schlatka, MC10
    READ MORE
  • TRNDS Danielle Edwards Jett Foundation
    TRNDS Speaker Danielle Edwards, Jett Foundation
    READ MORE
  • His daughter has a rare disorder. He’s developing a novel gene therapy.
    READ MORE
  • A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
    READ MORE
  • Study Presents Clinical, Genetic Landscape of Pompe Disease
    READ MORE

Latest Tweets

TRNDS Speakers

Room Block

Hilton Garden Inn
Rochester/University
Medical Center

30 Celebration Drive
Rochester, NY 14620

Phone: 585-424-4404

TRNDS Rate: $149/night